Licensing as a Commercialisation Strategy for German Biotechnology Firms

Due to a lack of resources in new high-tech firms market access is quite diffcult. Furthermore, they do not have a reputation in the market for reliable products. Contractual arrangements with more established firms, such as licensing agreements, are one way for new firms to profit from technological innovation. The aim of this study is to investigate how country differences between German and American biotechnology firms affect the usage of licensing as a commercialisation strategy.